Topology based radiomic feature derived from persistent homology predicts survival in non-small cell lung cancer patients treated with SBRT

Eashwar Somasundaram[1,*], **Raoul R. Wadhwa**[2], **Adam Litzler**[3], **Steph Owen**[4], **Peng Qi**[5], **Gregory Videtic**[5], **Kevin Stephans**[5], **Michael Kattan**[6], **and Jacob G. Scott**[1,4,5,+]

[1]Case Western Reserve University School of Medicine, Cleveland, OH 44195, USA
[2]Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA
[3]University of Colorado Boulder, Department of Applied Mathematics, Boulder, CO 80309, USA
[4]Lerner Research Institute, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH 44195, USA
[5]Taussig Cancer Institute, Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
[6]Lerner Research Institute, Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, USA
[*]Email: evs27@case.edu
[+]Correspondence: ScottJ10@ccf.org; 9500 Euclid Ave Desk NE-6, Cleveland, OH 44195, United States.

ABSTRACT

Introduction: There exist a wide range of clinical treatments for NSCLC, each with a corresponding range of outcomes. Risk calculators predicting overall survival would aid in treatment planning and prognosis counseling. Traditional risk calculators use clinical and histopathologic data to predict survival. We propose incorporating the PHOM score, the radiomic quantification of solid tumor topology, to predict overall survival.

Methods: Patients diagnosed with stage I or II NSCLC and status post SBRT were selected ($n = 554$). The PHOM score was calculated on each patient's pre-treatment CT scan. PHOM score, age, sex, stage, KPS, CCI, and post-SBRT chemotherapy were predictors in the generated Cox proportional hazards models for overall and cancer-specific survival. Patients were split into high and low PHOM score groups by median value and compared using KM curves for overall survival and cumulative incidence curves for cause specific death. Optimized tertile PHOM risk groups were calculated and similarly compared for overall survival and cause-specific death. Internal validation was conducted with bootstrap resampling and calibration curves were checked. Finally, a nomogram to predict overall survival was generated and is publicly available at https://eashwarsoma.shinyapps.io/LungCancerTDATest/.

Results: PHOM score was a significant predictor for overall survival (HR: 1.17, 95% CI: $1.07 - 1.28$) and was the only significant predictor for cancer-specific survival (1.31, 95% CI: $1.11 - 1.56$) in the multivariable Cox model. The median survival for the above median PHOM group was 888 days (95% CI: $719 - 1043$), which was significantly worse compared to the below median PHOM group ($1,382$ days (95% CI: $1220 - 1576$), $p < 0.001$). The above median PHOM group had a significantly greater chance of cancer-specific death at post treatment day 2,000 (0.244, 95%CI: $0.192 - 0.296$) compared to lower scorers (0.171, 95% CI: $0.123 - 0.218$, $p = 0.029$). Nomograms for 1, 2, 5, and 8-year overall survival were successfully calibrated using the Cox model.

Conclusions: The PHOM score is associated with cancer-specific survival and predictive of overall survival. Our developed nomogram can be used to inform clinical prognosis and assist in making post-SBRT treatment considerations.

Conflicts of Interest

The authors have no conflicts of interest to disclose, financial or otherwise, in relation this article.

Funding

JGS was supported by NIH grant R37 CA244613. ES and RRW were supported by the Case Comprehensive Cancer Center Summer Training Grant for medical students.

Keywords: non-small cell lung cancer, predictive model, radiomics, persistent homology, nomogram

1 Introduction

Approximately 230,000 cases of lung cancer are diagnosed and 135,000 patients die from lung cancer each year[1]. Proportionally, 85% of all lung cancer cases are non-small cell lung cancer (NSCLC)[2]. Primary therapy has traditionally been surgical resection; however, stereotactic body radiation therapy (SBRT) is now an option for patients with inoperable tumors[3]. For all cancers, clinical prognostication is essential for therapy selection. This is especially important in lung cancer, for which 5-year survival is highly variable in NSCLC ranging from nearly 70% for patients with stage I disease down to 10% for patients with metastatic disease[4].

Risk calculators are clinical decision support tools that quantify clinical prognosis. They typically use patient-specific histopathologic and clinical covariates to predict outcomes. Risk calculators incorporating molecular and clinical information have been developed for lung cancer[5]. Although clinical data is easy to obtain and incorporate in such risk models, collecting detailed molecular information often poses a challenge outside of tertiary medical centers. Imaging data is far more readily accessible. Radiomics - the science of extracting and analyzing features from imaging data - has been increasingly used to predict clinical outcomes in cancer[6]. While radiomics already offers a wide toolset for image analysis, we propose a valuable extension with persistent homology.

Persistent homology quantifies the global topology, or overall shape, of big data[7]. Analogously in the histologic context, oncology already features qualitative shape analysis through Gleason scoring to grade prostate cancer severity based on gland shape[8]. These high-level approaches provide the clear benefit of discriminating signal from noise. We believe that malignant and benign tissue exhibit distinct topology on clinical imaging. Widely used heuristics in clinical medicine support this intuition. For instance, malignant tumors are typically diffusely spread, heterogeneous in composition, and may possess necrotic cavities. On the other hand, benign tumors are usually well-circumscribed and more likely to be homogeneous in appearance[9]. Persistent homology simply formalizes and quantifies these observations to permit their use in predictive models. Of note, persistent homology has already been introduced to radiomics in the study of glioblastoma and liver cancer[10, 11].

Even within lung cancer, persistent homology has shown promise in predictive modeling via a metric named the PHOM score, which quantifies the texture of a solid tumor based on CT imaging data[12]. In our previous study, we demonstrated that the PHOM score is associated with overall survival. We hypothesize that the PHOM score can predict survival associated with NSCLC treated with SBRT. Here, we validate and extend the PHOM score using a large prospectively collected, IRB approved dataset from our institution including 554 patients treated with SBRT for primary lung cancers from 2008-2019. We combine our PHOM score with clinical covariates to develop prognostic nomograms that predict duration of overall survival post-diagnosis. Our validated PHOM score has the potential to stratify patients into risk categories, which can be useful for both future clinical trial stratification and treatment selection.

2 Materials and Methods

We developed a data pipeline that calculated the PHOM score of computed tomography (CT) tumor scans, generated regression models, and internally validated these models to predict survival. Methodology to generate a PHOM score using tumor CT scans is described in our previous work[12]. Only patients with early stage (I or II) primary non small cell lung cancer with no prior treatment history were eligible for this study. We utilized a prospectively collected dataset of CT scans for patients receiving SBRT entailing 803 scans with corresponding clinical data. After excluding 249 patients with metastatic disease, nodal disease, additional primary tumors, and patients who received pretreatment, 554 patients met inclusion criteria. All patients received SBRT therapy as their primary treatment for local control.

Each patient's primary lung tumor had been segmented by a radiation oncologist. For each lung tumor CT scan, we used the segmentation coordinates to crop the tumor CT scan to only include tumor tissue. A PHOM score was calculated from this data object. As previously described, this metric reflects the number of disconnected foci of pixels with similar gray scale values in the segmented tumor object[12].

PHOM Score, age, sex, Karnofsky Performance Status (KPS), Charlson Comorbidity Index (CCI), overall stage, and post radiation chemotherapy were included as covariates in a Cox Proportional Hazards Model for overall and cancer specific survival.

This cohort was divided into 2 groups by median PHOM score (PHOM $= -0.0372$) to compare trends in overall survival and trends in cumulative incidence by disease specific death. Kaplan Meier curves were drawn to compare overall survival between the two groups, and log-rank statistics were used to compare the survival trends. Cumulative incidence curves were drawn to compare cause of death between these 2 groups.

This analysis was repeated but with optimized tertiles. Tertiles were calculated by selecting the two PHOM score cutoff values that resulted in the maximal chi square value of the Kaplan Meier Curve. The low risk group (n = 211) was defined as below -0.460, medium risk group (n = 172) as between -0.460 and 0.668, and high risk group (n = 171) as above 0.668. Both Kaplan Meier curves and cumulative incidence curves were drawn for these three groups. The Benjamini-Hochberg correction

was used to correct for multiple comparisons for the Kaplan Meier pairwise comparisons.

The multivariable Cox proportional hazards model for overall survival was used to calibrate a nomogram to predict 1, 2, 5, and 8 year survival. Predicted median survival was calculated as a weighted sum of the individual survival predictions. This model was internally validated using bootstrap resampling (1,000 repetitions), and calibration curves were checked to ensure alignment of observed and optimism fitted survival rates. To assess the relative contribution of each covariate towards prediction ability of the multivariable Cox model for overall survival, the drop in C index was calculated by omitting each covariate one at a time from the full model. The C index has been routinely used to evaluate the discriminating ability of a survival model[13]. All data were processed and analyzed using R (v3.6.1) and Python (v3.7.6) [14–16]. Code with explanation for this data pipeline can be found at https://github.com/eashwarsoma/phom-lungca-ccf.

3 Results

This studied patient population were generally able bodied individuals with early stage NSCLC and a moderate number of comorbidities. **Table 1** provides a descriptive overview of the patient population. All patients had stage I or II primary non-small cell lung cancer (none had nodal disease). No patients in this cohort had treatment prior to stereotactic body radiation therapy (SBRT), but 26 patients (4.7%) had some form of post SBRT chemotherapy. KPS scores in this study ranged from $50 - 100$. Most patients had baseline independent functional status corresponding to a Karnofsky Performance Status (KPS) of 80 (215 patients) and $90 - 100$ (168 patients). Using an α/β ratio of 10, mean dose received over treatment course was $100.54 Gy$ (SD: $25.24 Gy$) EQD2. 89 patients had minimal comorbidity corresponding to a Charlson Comorbidity Index (CCI) of $2 - 4$. Most patients had additional comordbities with scores ranging from $5 - 8$. 60 patients had severe comorbidity (CCI > 8). 115 (20.8%) patients died from cancer, and 323 (58.3%) patients died from other causes. 116 patients (20.9%) were alive at last follow up, and the median follow up time for those alive was approximately 4.7 years (SD: 2.14 years).

Patient Characteristics

Label	level	Overall
n		554
Age, mean (SD)		74.35 (9.15)
Sex, mean (SD)	Male	263 (47.5)
	Female	291 (52.5)
Race (%)	Black	79 (14.3)
	White	459 (82.9)
	Other	16 (2.9)
Years Smoked, mean (SD)		52.25 (33.89)
EQD2, mean (SD)		100.54 (25.24)
Post SBRT Therapy (%)	No	528 (95.3)
	Yes	26 (4.7)
Overall Stage (%)	IA	363 (65.5)
	IB	121 (21.8)
	IIA	44 (7.9)
	IIB	26 (4.7)
Karnofsky Performance Status (%)	KPS = 50-60	44 (7.9)
	KPS = 70	127 (22.9)
	KPS = 80	215 (38.8)
	KPS = 90-100	168 (30.3)
Charlson Comorbidity Index (%)	CCI = 2-4	89 (16.2)
	CCI = 5	125 (22.7)
	CCI = 6	114 (20.7)
	CCI = 7	99 (18.0)
	CCI = 8	64 (11.6)
	CCI = 9-14	60 (10.9)
Cause of Death (%)	Alive at Last Follow Up	116 (20.9)
	Death by Cancer	115 (20.8)
	Death by Other Cause	323 (58.3)
Followup Time, mean (SD)		1715.72 (782.71)

Table 1. **Patient Characteristics of Study Cohort.** Patients in this cohort had early stage tumors, were generally healthy (high KPS), and had a moderate number of comorbidities (CCI: 5-8). 554 patients were present in the cohort. Followup time describes the mean number of days between treatment and most recent followup appointment for patients who were alive. EQD2: Equivalent Dose In 2-Gy Fractions, calculated using an α/β ratio of 10. KPS: Karnofsky Performance Score CCI: Charlson Comorbidity Index

PHOM score was a significant predictor of both overall survival (HR: 1.17; 95% CI: $1.07 - 1.28$, $p < 0.001$) and cancer specific survival (HR: 1.31; 95% CI: $1.11 - 1.56$, $p = 0.0014$) after controlling for age, functional status, comorbidity, treatment factors and stage. For cancer specific survival, the PHOM score was the only significant covariate in the multivariable model. **Figure 1** shows a forest plot of variable significance in a Cox Proportional Hazards Model for overall and cancer specific survival, and **Table 2** lists exact hazard ratios. For overall survival, high functional status of KPS $= 90 - 100$ was protective for survival (HR: 0.46, 95% CI: $0.32 - 0.67$, $p < 0.001$). Increased comorbidity was also associated with poor overall survival in the multivariable model (HR: 2.54, 95% CI: $1.69 - 3.80$, $p < 0.001$). **Supplemental Table 1** shows the p-values for the Cox Proportional Hazards models.

Figure 1. **Forest Plot of Overall and Cancer Specific Cox Proportional Hazards Models.** The PHOM Score was a significant covariate for both overall and cancer specific survival. Bands represent 95% confidence intervals. KPS (Karnofsky performance status) is compared against KPS $= 50 - 60$. CCI (Charlson Comorbidity Index) is compared against CCI $= 2 - 4$. Stage covariates are compared against Stage 1a.

Cox Proportional Hazards Model

	Overall Survival UV Hazard Ratio	Overall Survival MV Hazard Ratio	Cancer Specific Survival UV Hazard Ratio	Cancer Specific Survival MV Hazard Ratio
PHOM Score	**1.21 (1.13-1.30)**	**1.17 (1.07-1.28)**	**1.35 (1.19-1.54)**	**1.31 (1.11-1.56)**
Age at Diagnosis	**1.01 (1.00-1.02)**	1.00 (0.99-1.02)	1.00 (0.98-1.02)	0.99 (0.97-1.02)
Male Sex	1.19 (0.99-1.44)	**1.27 (1.05-1.55)**	1.01 (0.70-1.46)	0.98 (0.67-1.45)
KPS = 70	0.78 (0.54-1.13)	0.76 (0.52-1.10)	0.81 (0.38-1.75)	0.85 (0.39-1.86)
KPS = 80	**0.63 (0.45-0.89)**	**0.63 (0.44-0.90)**	0.72 (0.35-1.47)	0.81 (0.39-1.69)
KPS = 90-100	**0.47 (0.33-0.67)**	**0.46 (0.32-0.67)**	0.62 (0.30-1.30)	0.65 (0.30-1.40)
CCI = 5	**1.59 (1.14-2.22)**	1.41 (0.99-2.00)	1.30 (0.71-2.36)	1.22 (0.65-2.28)
CCI = 6	1.30 (0.93-1.83)	1.21 (0.86-1.72)	1.27 (0.71-2.29)	1.45 (0.78-2.69)
CCI = 7	**1.75 (1.24-2.48)**	**1.77 (1.23-2.56)**	1.20 (0.63-2.29)	1.51 (0.76-3.03)

CCI = 8	**2.00 (1.37-2.92)**	**2.03 (1.36-3.02)**	1.17 (0.55-2.47)	1.34 (0.61-2.97)
CCI = 9-14	**2.70 (1.83-3.98)**	**2.54 (1.69-3.80)**	1.42 (0.64-3.19)	1.72 (0.74-3.99)
Post-Radiation Chemo	0.96 (0.63-1.48)	1.01 (0.64-1.58)	**1.90 (1.02-3.54)**	1.65 (0.84-3.22)
Stage 1b	**1.46 (1.17-1.84)**	1.23 (0.94-1.61)	1.45 (0.92-2.30)	0.96 (0.56-1.65)
Stage 2a	**1.85 (1.30-2.64)**	1.28 (0.85-1.92)	**2.60 (1.43-4.73)**	1.47 (0.73-2.96)
Stage 2b	**1.80 (1.16-2.78)**	1.33 (0.84-2.11)	**2.28 (1.05-4.98)**	1.45 (0.62-3.38)

Table 2. Cox Proportional Hazards Model for Overall and Cancer Specific Survival. The PHOM Score was a significant covariate for survival even after controlling for clinical variables. KPS and CCI were significant covariates for overall survival but not in cancer specific survival. Values are given as hazard ratio (95% Confidence Interval). KPS (Karnofsky Performance Status) is compared against KPS $= 50 - 60$. CCI (Charlson Comorbidity Index) is compared against CCI of $2 - 4$. Stage covariates are compared against Stage 1a. Bolded values are statistically significant with $p < 0.05$. P-values for this table are included as **Supplemental Table 1**.

The PHOM score produced well defined risk categories for overall survival and cancer death incidence when stratified by median or optimized cutoff values. **Figure 2A** describes the survival differences by PHOM score groups stratified by the cohort's median PHOM score. Patients in high PHOM group had significantly worse survival ($p < 0.001$) compared to patients in low PHOM score group. Patients in the lower PHOM score group had a median survival of 1382 days (95% CI: $1220 - 1576$), which was significantly higher compared to patients in the higher PHOM score group (median: 888 days, 95% CI: $719 - 1043$, $p < 0.001$). We next hypothesized that the PHOM score could delineate risk groups at higher resolution, and so chose two cutpoints of PHOM score to optimally separate the cohort into three groups of low, intermediate and high probability of death. **Figure 2B** describes the survival differences predicted by these optimized PHOM score risk groups. The median survival for the high PHOM risk group was 783 days (95% CI: $635 - 944$). This was significantly less than both the medium ($p = 0.020$) and low risk PHOM score groups ($p < 0.001$). The median survival for the medium and low risk groups were $1,060$ days (95% CI: $911 - 1,365$) and $1,431$ days (95% CI: $1,245 - 1,767$) respectively. The medium risk group also had significantly worse survival compared to the low risk group ($p < 0.001$).

PHOM score strata delineates cancer specific death incidence curves but not death incidence curves due to other causes. **Figure 3A** compares cause specific death between PHOM score groups divided by cohort median. Having an above median PHOM score was associated with a 0.244 (95% CI: $0.192 - 0.296$) chance of cancer specific death by day $2,000$, which was significantly higher compared to the below median PHOM score chance of death at 0.171 (95% CI: $0.123 - 0.218$, $p = 0.029$). However, for other causes of death, a high vs low PHOM score corresponded to a nonsignificant 0.582 (95% CI: $0.521 - 0.642$) vs 0.499 (95% CI: $0.436 - 0.563$) chance of death by day $2,000$. **Figure 3B** compares cause specific death among PHOM score groups divided by optimized PHOM score risk groups. Similarly, the difference among incidence of death at day 2000 was significant when assessing cancer death ($p = 0.0013$) but not other death. For low, medium, and high risk PHOM score groups, the chance of cancer death by day 2000 was 0.146 (95% CI: $0.0950 - 0.197$), 0.194 (95% CI: $0.133 - 0.255$), and 0.296 (95% CI: $0.224 - 0.366$) respectively. For low, medium, and high risk PHOM score groups, the chance of death from other causes by day 2000 was 0.474 (95% CI: $0.401 - 0.546$), 0.612 (95% CI: $0.535 - 0.689$), and 0.551 (95% CI: $0.474 - 0.629$) respectively.

We drew nomograms, which are user friendly visual tools that represent the underlying survival regression models. Nomograms were calibrated for 1, 2, 5, and 8-year overall survival. The model was internally validated using bootstrap resampling ($1,000$ repetitions), and calibration curves are shown in **Supplemental Figure 1**. The apparent and optimism bias corrected curves showed relatively strong alignment with the ideal curve indicating that our model is internally valid and not overfitted. **Supplemental Figure 2** demonstrates the relative contribution of each covariate to the predictive ability of the multivaraite Cox model with relative drop in C index.

Each covariate from the multivariable Cox Proportional Hazards Model is associated with a certain point value, and summing the point values for a given patient's parameter generates a score that can be used to assign 1, 2, 5, and 8 year overall survival chance. The weighted sum of these survival chances gives the predicted median survival. An online interactive version of this nomogram is available at `https://eashwarsoma.shinyapps.io/LungCancerTDATest/`.

4 Discussion

Non-small cell lung cancer is associated with a wide range of treatment modalities and prognostic outcomes. There is currently no good metric that describes risk and survival in patients who receive primary treatment with SBRT. Radiomics processes raw imaging data into new meaningful results. And since imaging data is widely available compared to molecular data, radiomic metrics are accessible to all levels of healthcare. We show our novel topologically inspired radiomics variable serves as a useful metric to assist patients in understanding their prognosis, clinicians in selecting treatments, and potentially clinical trialists in risk stratifying for clinical trials.

The PHOM score generated from tumor CT scans predicts overall survival in early stage non-small cell lung cancer. Stratifying PHOM score by median groups reveals worse overall and cancer specific survival in patients in the higher PHOM

Figure 2. **Kaplan Meier Overall Survival by PHOM Score.** Stratifying the cohort by median PHOM score groups and optimized cutoffs produced well demarcated survival curves. **(A)** The median survival for the above median PHOM group was 888 days (95% CI: $719 - 1,043$). The median survival for the below median PHOM group was significantly higher at $1,382$ days (95% CI: $1,220 - 1,576$, $p < 0.001$). **(B)** The median survival for the high PHOM risk group was 783 days (95% CI: $635 - 944$). This was significantly less than both the medium ($p = 0.020$) and low risk PHOM score groups ($p < 0.001$). The median survival for the medium risk group was $1,060$ days (95% CI: $911 - 1,365$). This was significantly less than the low risk PHOM score group ($p < 0.001$). The median survival for the low risk group was $1,431$ days (95% CI: $1,245 - 1,767$). The $*$, $**$, and $***$ represent $p < 0.05$, $p < 0.01$, and $p < 0.001$ respectively.

Figure 3. **Cumulative Incidence of Death by Specific Cause** Stratifying the cohort by median PHOM score groups and optimized cutoffs produced well demarcated cumulative incidence curves for cancer specific death but not death due to other causes. **(A)** Having an above median PHOM score was associated with a 0.244 (95% CI: $0.192 - 0.296$) chance of cancer specific death by day $2,000$. A below median PHOM score was associated with a significantly less chance of death by day $2,000$ at 0.171 (95% CI: $0.123 - 0.218$, $p = 0.029$). However, for other causes of death, a high vs low PHOM score corresponds to a nonsignificant 0.582 (95% CI: $0.521 - 0.642$) vs 0.499 (95% CI: $0.436 - 0.563$) chance of death by day $2,000$. **(B)** For low, medium, and high risk PHOM score groups, the chance of cancer death by day 2000 was 0.146 (95% CI: $0.0950 - 0.197$), 0.194 (95% CI: $0.133 - 0.255$), and 0.296 (95% CI: $0.224 - 0.366$) respectively. For low, medium, and high risk PHOM score groups, the chance of death from other causes by day 2000 was 0.474 (95% CI: $0.401 - 0.546$), 0.612 (95% CI: $0.535 - 0.689$), and 0.551 (95% CI: $0.474 - 0.629$) respectively. Similarly, the difference among incidence of death at day 2000 was significant when assessing cancer death ($p = 0.0013$) but not other death.

Figure 4. **Nomogram for Overall Survival.** This nomogram is a visual tool to convert the variables in our Cox overall survival model into a common risk score. This risk score can then convert into predicted survival. An online interactive version of this nomogram is available at https://eashwarsoma.shinyapps.io/LungCancerTDATest/. KPS: Karnofsky Performance Status. CCI: Charlson Comorbdity Index.

score half. However, when assessing incidence of death due to other causes, being in the higher PHOM score half is not associated with increased death rates. It appears that the PHOM score is a true reflection of cancer severity as it differentiates cancer-specific survival incidence curves but does not affect death from other causes (**Figure 2** and **Figure 3**). Similarly, our risk category tertile groups demonstrate worse overall and cancer specific survival among the higher risk groups. As mentioned earlier, the PHOM score may be used by trialists in risk stratifying, and we offer our tertile groups as one possible method of stratification.

In our cancer-specific Cox models, KPS and CCI do not affect cancer-specific survival in the multivariable model, which is somewhat expected as these measure overall health rather than tumor progression specifically (**Table 2**). The PHOM score is the only significant predictor for cancer specific survival in the multivariable model. In addition, all lesions were all treated with SBRT at the time of staging, which is known to have very high local control rates[17]. The KPS had the greatest drop in C index score, and CCI and PHOM score resulted in similar C index drops. This roughly reflects the importance these metrics have in the predictive power of overall survival (**Supplemental Table 2**). We postulate that in our model that a greater PHOM score increases probability of cancer specific death whereas CCI and KPS reflect probability of death from other causes. Since these cancers are treated early stage, patients tend to die from comorbidities, so it was improtant to include large picture clincial variables like CCI and KPS in our model. The overlapping of the calibration curves of apparent, bias-corrected, and ideal survival demonstrate strong internal validity of our predictive overall survival nomogram (**Supplemental Figure 1**).

To our knowledge, this is the first paper that utilizes persistent homology of CT scans to predict overall survival in lung cancer. We have built on our prior work where we developed the PHOM score[12]. However, our prior work was limited to demonstrating statistical association with overall survival and did not include important covariates such as KPS and CCI due to limitations in available data. We speculate our metric is a measure of underlying structural tissue heterogeneity. Increased tissue heterogeneity is a possible sign of a more aggressive tumor which is why our metric correlates well with cancer specific survival and predicts overall survival. Our new imaging persistent homology metric adds to the other metrics that have been developed for glioblastoma, breast, and prostate cancer clinical outcomes research[8, 10, 18].

Persistent homology has opened up an entirely new suite of tools for radiomics analysis of imaging data. In particular, results based on the PHOM score have strong external validity as the same score was previously significantly associated with NSCLC survival in the publicly available The Cancer Imaging Archive dataset[12], and here is a significant predictor of

NSCLC survival in a distinct dataset. Traditional radiomics features have been used to predict tumor histology and needed dose to prevent cancer recurrence[19, 20]. Topology is not currently a standard variable in radiomics, so it is not known how it could interact. We have shown that the PHOM score independently predicts survival in NSCLC even after controlling for traditional clinical metrics. How the PHOM score could interact with traditional Radiomic measures that have already demonstrated clinical utility in NSCLC remains to be answered. Additionally, the PHOM score could be incorporated with other non imaging data. Genomic models such as the genomically adjusted radiation dose (GARD) have been developed to predict individualized response to different radiation doses[21] and have been found to be predictive of individual patient outcome in a large meta-analysis[22]. We forsee future clinical models that incorporate genomic, imaging, and other modalities of data to more precisely guide therapy.

While our results are promising for NSCLC, some limitations must be considered. Primarily, our nomogram is only validated for patients with early stage NSCLC who receive SBRT therapy as their primary treatment modality with no surgery or prior chemotherapy. Therefore, this calculator is not yet valid for patients with lung resections, which is a common procedure in lung cancer patients. Additionally, we could not generate a cancer specific survival curve due to poor calibration curves when validating such a model. We believe this to be a result of the limited number of cancer specific deaths in this cohort, likely due to the fact that all patients had treated early stage lung cancer. Publicizing this nomogram, recruiting data from other institutions, and conducting prospective studies with longer follow up could address these limitations in future studies. Additionally, future studies could analyze how the PHOM score fits in with traditional radiomics characteristics. The widespread imaging capability of modern hospitals makes imaging analysis such as computing the PHOM score practical to utilize in daily patient care. In cohort studies or randomized controlled trials, the PHOM score could be used to stratify patients into risk categories to investigate who might benefit from adjuvant therapy. Long term, we envision the creation of a risk calculator that extracts the most useful features of an imaging data that can both prognosticate and help make clinical decisions.

Acknowledgments

The authors thank members of Theory Division for their constructive feedback and valuable input in this project. We thank Jessica Scarborough, PhD for advice and code to generate optimal PHOM score tertiles.

Author contributions statement

All authors made substantial contributions to: (1) the conception and design of the study or acquisition, analysis, and interpretation of the data; (2) draft the article or revising it critically for important intellectual content; (3) final approval of the submitted version.

References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. *CA: A Cancer J. for Clin.* **70**, 7–30, DOI: 10.3322/caac.21590 (2020).

2. Duma, N., Santana-Davila, R. & Molina, J. R. Non–small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. *Mayo Clin. Proc.* **94**, 1623–1640, DOI: 10.1016/j.mayocp.2019.01.013 (2019).

3. Chang, J. Y. *et al.* Stereotactic ablative radiotherapy for operable stage i non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. *The Lancet Oncol.* **22**, 1448–1457, DOI: 10.1016/s1470-2045(21)00401-0 (2021).

4. Goldstraw, P. *et al.* The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J. Thorac. Oncol.* **11**, 39–51, DOI: 10.1016/j.jtho.2015.09.009 (2016).

5. Sperduto, P. W. *et al.* Estimating survival in patients with lung cancer and brain metastases. *JAMA Oncol.* **3**, 827, DOI: 10.1001/jamaoncol.2016.3834 (2017).

6. Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: Images are more than pictures, they are data. *Radiology* **278**, 563–577, DOI: 10.1148/radiol.2015151169 (2016).

7. Carlsson, G. Topology and data. *Bull. Am. Math. Soc.* **46**, 255–308 (2009).

8. Gordetsky, J. & Epstein, J. Grading of prostatic adenocarcinoma: current state and prognostic implications. *Diagn. Pathol.* **11**, DOI: 10.1186/s13000-016-0478-2 (2016).

9. AI, B. & Oncology, C. C. C. *Comparative Oncology* (Bucharest: The Publishing House of the Romanian Academy, 2007).

10. Crawford, L., Monod, A., Chen, A. X., Mukherjee, S. & Rabadán, R. Predicting clinical outcomes in glioblastoma: An application of topological and functional data analysis. *J. Am. Stat. Assoc.* 1–12, DOI: 10.1080/01621459.2019.1671198 (2019).

11. Oyama, A. *et al.* Hepatic tumor classification using texture and topology analysis of non-contrast-enhanced three-dimensional t1-weighted MR images with a radiomics approach. *Sci. Reports* **9**, DOI: 10.1038/s41598-019-45283-z (2019).

12. Somasundaram, E., Litzler, A., Wadhwa, R., Owen, S. & Scott, J. Persistent homology of tumor CT scans is associated with survival in lung cancer. *Med. Phys.* **48**, 7043–7051 (2021).

13. Pencina, M. J. & D'Agostino, R. B. OverallC as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. *Stat. Medicine* **23**, 2109–2123, DOI: 10.1002/sim.1802 (2004).

14. R Core Team. *R: A Language and Environment for Statistical Computing.* R Foundation for Statistical Computing, Vienna, Austria (2012). ISBN 3-900051-07-0.

15. RStudio Team. *RStudio: Integrated Development Environment for R.* RStudio, PBC., Boston, MA (2020).

16. Van Rossum, G. & Drake, F. L. *Python 3 Reference Manual* (CreateSpace, Scotts Valley, CA, 2009).

17. Sebastian, N. T., Xu-Welliver, M. & Williams, T. M. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. *J. Thorac. Dis.* **10**, S2451–S2464, DOI: 10.21037/jtd.2018.04.52 (2018).

18. Nicolau, M., Levine, A. J. & Carlsson, G. Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. *Proc. Natl. Acad. Sci.* **108**, 7265–7270, DOI: 10.1073/pnas.1102826108 (2011).

19. Woody, N. M. *et al.* A histologic basis for the efficacy of SBRT to the lung. *J. Thorac. Oncol.* **12**, 510–519, DOI: 10.1016/j.jtho.2016.11.002 (2017).

20. Lou, B. *et al.* An image-based deep learning framework for individualising radiotherapy dose: a retrospective analysis of outcome prediction. *The Lancet Digit. Heal.* **1**, e136–e147, DOI: 10.1016/s2589-7500(19)30058-5 (2019).

21. Scott, J. G. *et al.* A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. *The Lancet Oncol.* **18**, 202–211, DOI: 10.1016/s1470-2045(16)30648-9 (2017).

22. Scott, J. G. *et al.* Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (gard): a cohort-based pooled analysis. *The Lancet Oncol.* **22**, 1221–1229 (2021).